Myositis Treatment Pipeline Robust With Over 40 Pharma Companies
A DelveInsight analysis reveals over 40 pharmaceutical companies are actively developing new therapies for myositis. Multiple drug candidates are progressing through clinical trials.
Over 40 pharmaceutical companies are actively engaged in the development of treatments for myositis, a group of rare inflammatory muscle diseases, according to a report by DelveInsight. The "Myositis Pipeline Insight 2026" report details the progress of more than 45 drug candidates, encompassing both clinical and non-clinical stages.
Recent clinical trial initiations highlight significant advancements by major pharmaceutical players. AstraZeneca has begun a Phase III study for subcutaneous anifrolumab in moderate to severe idiopathic inflammatory myopathies. Janssen Research & Development is evaluating nipocalimab in a Phase II study, while argenx is assessing efgartigimod PH20 SC in a Phase II/III trial.
Further development efforts are underway by companies such as Cabaletta Bio, which is investigating the cell therapy CABA-201 in a Phase I/II study, and Priovant Therapeutics Inc., initiating a Phase III trial for brepocitinib in dermatomyositis. Pfizer is also advancing its Phase III study for PF-06823859, a monoclonal antibody targeting inflammatory pathways.
The myositis pipeline is characterized by a broad range of active players, including Pfizer, Galapagos NV, and Bristol-Myers Squibb, and a diverse set of therapeutic approaches. These efforts aim to address the underlying causes of muscle inflammation and weakness associated with the condition.
Myositis encompasses several rare conditions causing muscle inflammation and weakness. Diagnosis and treatment strategies vary by specific type and severity, often involving corticosteroids, immunosuppressants, and supportive care to manage symptoms and disease progression.